Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.

ABSTRACT:

SUBMITTER: Barretina-Ginesta MP 

PROVIDER: S-EPMC9511290 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature